Audio By Carbonatix
Breast cancer can resurface after remaining dormant for 15 years following successful treatment, a study has found.
Women with large tumours and cancer that had spread to the lymph nodes had the highest 40% risk of it coming back.
Researchers writing in the New England Journal of Medicine said extending treatment with hormone therapy could reduce the risk of it recurring.
Scientists analysed the progress of 63,000 women for 20 years.
All had the most common form of breast cancer.
This is a type fuelled by the hormone oestrogen which can stimulate cancer cells to grow and divide.
Every patient received treatments such as tamoxifen or aromatase inhibitors which block the effects of oestrogen or shut off the hormone's supply.
Although after five years of treatment their cancers had gone, over the next 15 years a steady number of women found that their cancer spread throughout their body - some up to 20 years after diagnosis.
Women who originally had large tumours and cancer that had spread to four or more lymph nodes were at highest risk of the cancer returning the next 15 years, the study said.
Women with small, low-grade cancers and no spread to the lymph nodes had a much lower 10% risk of cancer spread over that time.
'Remarkable'
Lead researcher Dr Hongchao Pan, from University of Oxford, said: "It is remarkable that breast cancer can remain dormant for so long and then spread many years later, with this risk remaining the same year after year and still strongly related to the size of the original cancer and whether it had spread to the (lymph) nodes."
Doctors have long known that five years of tamoxifen reduces the risk of recurrence by about a third in the five years after stopping treatment.
Recent research has suggested that extending hormone therapy to 10 years may be more effective at preventing breast cancer recurrence and death.

But there are side effects with hormone treatments which can affect patients' quality of life and cause them to stop taking the pills.
These include menopausal symptoms, osteporosis, joint pain and carpal tunnel syndrome.
Prof Arnie Purushotham, senior clinical adviser at Cancer Research UK, which funded the study, said that since the research began, new drugs had been used to treat breast cancer and those worked in different ways to tamoxifen.
He said: "It's vital that work continues to better predict which cancers might return.
"We also need to know what the difference for women might be in taking hormone therapies for 10 years instead of five, the side effects and how this affects patients' quality of life."
Latest Stories
-
GPL 2025/26: Asante Kotoko draw with GoldStars to extend winless run
3 hours -
Fire guts temporary wooden structures at Afful Nkwanta in the Ashanti Region
4 hours -
Haruna Iddrisu didn’t approve gender identity content – Education Ministry
5 hours -
‘We are not for sale’: Thousands rally in Greenland and Denmark against Trump’s annexation threat
5 hours -
Deputy Education Minister directs GES to act on video of SHS students displaying charms
5 hours -
From camouflage to tracksuits – Guinea’s junta leader becomes civilian president
5 hours -
Iran supreme leader admits thousands killed during recent protests
5 hours -
Judiciary to roll out court decongestion measures, galamsey courts – Chief Justice
6 hours -
Ugandan leader to extend 40-year rule after being declared winner of contested poll
7 hours -
Residents demand action on abandoned Salaga–Kumdi–Kpandai road
7 hours -
Ghana, Japan explore ways to deepen long-standing bilateral ties
7 hours -
Ghana Navy foils illegal fuel bunkering operation along Volta coastline
8 hours -
Gov’t assures minimal power disruption during WAPCo gas pipeline maintenance
8 hours -
Burna Boy and Sporty Group unveil new single “For Everybody” celebrating Africa’s sports heritage and cultural excellence
8 hours -
Achieve By Petra partners Richie Mensah to drive financial independence
8 hours
